CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Ionetix

Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. Cardiac PET with Ammonia N-13.

KBP Biosciences

At KBP we are consistently reminded that patient care is the end goal of what we do daily.

Trio Health

Trio Health offers a unique collaboration with clinical experts, patients and specialty pharmacies to allow unparalleled insight into patient care. Together with our advisory boards, we created Trio Health MDX, a proprietary system to collect and share information from all three stakeholders. This innovative collaboration provides the patient with unprecedented care thereby improving patient outcomes.

OPEN Health

We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals, headquartered at Pune in West India, is an Indian pharmaceutical company.